SyntheMed reports positive results for Repel open-heart trial

By Elaine Rigoli

Tampa, Fla., Sept. 6 - SyntheMed, Inc. said its multi-center, randomized, masked pivotal clinical trial of Repel-CV in neonatal patients who underwent staged, open-heart surgical procedures met its primary clinical endpoint based on the level of reduction in the extent and severity of adhesions.

Repel-CV is a bioresorbable film designed to be placed over the surface of the heart at the conclusion of surgery to reduce the formation of post-operative adhesions (scar tissue), the company said in a news release.

The Iselin, N.J.-based biomaterials company said more than 70% of patients were completely free of clinically significant adhesions, the most severe grade of adhesions measured, as compared to less than 30% in the control patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.